Psoriasis during natalizumab treatment for multiple sclerosis

J Neurol. 2012 Dec;259(12):2758-60. doi: 10.1007/s00415-012-6713-1. Epub 2012 Oct 25.


Beta-interferon therapy is known to trigger psoriasis, but this effect has not been previously reported for other multiple sclerosis treatments, such as natalizumab. The following is a case report. A 31-year-old woman affected by psoriasis and relapsing-remitting multiple sclerosis suffered a severe worsening of psoriasis symptoms during natalizumab treatment and acquired a drug-resistant course. This case suggests that aggravation of psoriasis might be a rare side effect of natalizumab, and that clinicians should be aware of the possibility of paradoxical activation of autoimmune diseases during its treatment.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Multiple Sclerosis / complications*
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy*
  • Natalizumab
  • Psoriasis / complications
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Treatment Outcome


  • Antibodies, Monoclonal, Humanized
  • Natalizumab